Literature DB >> 12237323

Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells.

Ursula G B Haider1, Dan Sorescu, Kathy K Griendling, Angelika M Vollmar, Verena M Dirsch.   

Abstract

Resveratrol (RV), a polyphenolic substance found in grape skin, is proposed to account in part for the protective effect of red wine in the cardiovascular system. Angiotensin II (Ang II)-induced hypertrophy of vascular smooth muscle cells (VSMCs) is a pivotal step in the development of cardiovascular disease. The aims of this study were to test the hypothesis that RV may alter Ang II-mediated hypertrophic VSMC growth and to identify the putative underlying signaling pathways. We show that RV indeed potently inhibits Ang II-induced [(3)H]leucine incorporation in a concentration-dependent manner (50 microM RV, 71% inhibition). Western blot analysis reveals that phosphorylation of Akt/protein kinase B (PKB) and to a lesser extent the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) 1/2, both essentially involved in Ang II-mediated hypertrophy, is dose dependently reduced by RV. Consistent with these results, we show that RV attenuates phosphorylation of the p70 ribosomal protein S6 kinase (p70(S6K)), a kinase downstream of the ERK 1/2 as well as the Akt pathway, that is implicated in Ang II-induced protein synthesis. Upstream of Akt/PKB RV seems to mediate its antihypertrophic effect by inhibiting phosphorylation of the phosphatidylinositol 3-kinase (PI(3)K) rather than by activating phosphatases. In summary, we demonstrate for the first time that RV inhibits Ang II-induced VSMC hypertrophy, possibly by interfering mainly with the PI(3)K/Akt and p70(S6K) but also with the ERK 1/2 signaling pathway. Thus, this study delivers important new insight in the molecular pathways that may contribute to the proposed beneficial effects of RV in cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237323     DOI: 10.1124/mol.62.4.772

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Authors:  Michael L Paffett; Selita N Lucas; Matthew J Campen
Journal:  Vascul Pharmacol       Date:  2011-11-25       Impact factor: 5.773

2.  Early endosomal antigen 1 (EEA1) is an obligate scaffold for angiotensin II-induced, PKC-alpha-dependent Akt activation in endosomes.

Authors:  Rafal Robert Nazarewicz; Gloria Salazar; Nikolay Patrushev; Alejandra San Martin; Lula Hilenski; Shiqin Xiong; R Wayne Alexander
Journal:  J Biol Chem       Date:  2010-11-20       Impact factor: 5.157

3.  Hypothalamic Sirt1 regulates food intake in a rodent model system.

Authors:  Işin Cakir; Mario Perello; Omar Lansari; Norma J Messier; Charles A Vaslet; Eduardo A Nillni
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

Review 4.  Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells.

Authors:  Mary Jo Atten; Ernesto Godoy-Romero; Bashar M Attar; Thomas Milson; Matthew Zopel; Oksana Holian
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

5.  Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt.

Authors:  Anita Y M Chan; Vernon W Dolinsky; Carrie-Lynn M Soltys; Benoit Viollet; Shairaz Baksh; Peter E Light; Jason R B Dyck
Journal:  J Biol Chem       Date:  2008-06-18       Impact factor: 5.157

6.  Nutrients: the environmental regulation of cardiovascular gene expression.

Authors:  Marilena Minieri; Paolo Di Nardo
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

7.  Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy.

Authors:  Tzu-Hurng Cheng; Ju-Chi Liu; Heng Lin; Neng-Lang Shih; Yen-Ling Chen; Meng-Ting Huang; Paul Chan; Ching-Feng Cheng; Jin-Jer Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-09       Impact factor: 3.000

Review 8.  Validation of anti-aging drugs by treating age-related diseases.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-03-28       Impact factor: 5.682

Review 9.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

10.  PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN.

Authors:  K M Rice; S Uddemarri; D H Desai; R G Morrison; R Harris; G L Wright; E R Blough
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-11-17       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.